DOI: 10.4103/hjo.hjo_9_26 ISSN: 2949-706X

Comparison between intravitreal and sub-Tenon triamcinolone acetonide injection for sight-threatening diabetic retinopathy

Jaiswal Himanshi, Ziaul Haq Yasir, Singh Tushar Kant, Sharma Rakesh
Show PDF Cite

Abstract

Objectives:

Triamcinolone acetonide (TA) is commonly prescribed for treating macular edema caused by sight-threatening diabetic retinopathy (STDR). TA can be administered via intravitreal TA (IVTA) or posterior sub-Tenon’s triamcinolone injection (PSTI) methods. This study aims to assess and compare the visual and anatomical outcomes, as well as the safety profile, of IVTA and PSTI methods in STDR patients.

Materials and Methods:

This study included 70 diabetic patients with STDR attending our Medical College. Patients were assigned via block randomization to one of two groups: Group A received IVTA, while Group B received PSTI. P values below 0.05 were deemed statistically significant.

Results:

Both groups demonstrated comparable baseline characteristics, including age, sex, diabetes profile, intraocular pressure (IOP), best-corrected visual acuity (BCVA), and central macular thickness (CMT). Following treatment, Group A showed a significant increase in IOP at 8 weeks and 12 weeks ( P < 0.001), while Group B showed no significant change ( P = 0.867). Both groups experienced significant improvements in BCVA, evident at 4 weeks ( P = 0.026), 8 weeks ( P = 0.006), and 12 weeks ( P = 0.010). No significant difference in CMT was observed in between the groups, although individually, it was statistically significant. A slight positive correlation between age and IOP was observed in both groups, but it was not statistically significant. The correlation between the duration of diabetes and IOP, BCVA, and CMT was nonsignificant in either of the groups

Conclusion:

Both IVTA and PSTI methods effectively improved BCVA and CMT in STDR patients. However, PSTI demonstrated superior safety by minimizing IOP elevation, making it a preferable option for patients with glaucoma risk.

More from our Archive